StreetAlpha.app
Home › Stocks › BIOA

BioAge Labs, Inc. (BIOA)

Healthcare
$4.28
▼ −9.13%
LAST CLOSE · NOV 20

BioAge Labs develops drug candidates for cardiometabolic diseases, using human aging biology to identify its drug targets. It last closed at $4.28 on Nov 20, down 9.13% on the day. The next earnings report for BIOA is expected around Tue, Mar 23, 2027. For the quarter ended Sep 2026, BIOA reported EPS of -$0.73 on revenue of $298,000, with revenue down 85.5% from a year ago. Over its last 8 reports the stock moved an average of 3.6% the session after earnings. Over the last 12 months BIOA insiders bought $0 of stock on the open market and sold $7.8M, according to SEC Form 4 filings.

AI Auto Pilots
Is BIOA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold BIOA.

Key Stats

Last 12 months
Results
Revenue
$8.6M
+45.3% vs a year ago
Net income
−$107.8M
−1253.6% margin
EPS (diluted)
−$2.56
−118.8% vs a year ago
Free cash flow
−$103.0M
−1197.8% margin
Valuation
Market cap
$196.7M
46.0M shares
P/E
–
No P/E while losing money
Price to sales
22.9
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$52.7M
At Sep 30
Shareholder equity
$346.4M
Shares outstanding
46.0M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $0$0FY2024FY2025: $9.0M$9.0MFY2025

From BIOA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 23
Estimated date · Time not announced
Reported EPS
-$0.73
Quarter ended Sep 2026
Year ago EPS
-$0.56
Same quarter last year
Revenue
$298,000
−85.5% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $15.13Dec '24Mar 2025: -$0.36Mar '25Jun 2025: -$0.60Jun '25Sep 2025: -$0.56Sep '25Dec 2025: -$0.72Dec '25Mar 2026: -$0.52Mar '26Jun 2026: -$0.58Jun '26Sep 2026: -$0.73Sep '26Latest -$0.73
Revenue by quarter
Dec 2024: $0Dec '24Mar 2025: $1.5MMar '25Jun 2025: $2.4MJun '25Sep 2025: $2.1MSep '25Dec 2025: $3.1MDec '25Mar 2026: $2.8MMar '26Jun 2026: $2.5MJun '26Sep 2026: $298,000Sep '26Latest $298,000
How BIOA moved after its last 8 reports
Average move the session after a report ±3.6%
Nov 5, 2026After the close−3.6%
Aug 5, 2026After the close+2.6%
May 8, 2026Time not announced+0.9%
Mar 24, 2026Time not announced−13.5%
Nov 6, 2025After the close−2.8%
Aug 6, 2025After the close−0.2%
May 6, 2025After the close+2.8%
Mar 20, 2025After the close+2.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on BIOAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on BIOA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on BIOA

Technical Analysis

BIOA · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 28% below its 20 day and 44% below its 50 day average. It is 244% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the 52 week low at $4.24, and the nearest resistance the Pivot at $4.44.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 10.5%/day
Key levels
$25.9552 week high+506.3%
$14.74200 day average+244.4%
$10.71100 day average+150.2%
$6.1850 day average+44.4%
$5.70Swing high (Oct 21)+33.2%
$5.4720 day average+27.8%
$4.64Pivot R1+8.4%
$4.44Pivot+3.7%
$4.28Last close
$4.2452 week low−0.9%
$4.08Pivot S1−4.7%
Indicators
RSI (14)26.89Oversold below 30Oversold
MACD-0.43Below its signal lineBearish
Stochastic5.3Near the bottom of its rangeOversold
ADX (14)22.7Weak trend
Williams %R-97.8Oversold below −80, overbought above −20Oversold
CCI (20)-190.7Oversold below −100, overbought above 100Oversold
Rate of change−19.9%Change over 10 sessionsBearish
ATR (14)$0.45Typical daily range, 10.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for BIOA

What happened before

See how BIOA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Whale Options Flow

90D
Whale options flow for BIOAHow many large options trades hit BIOA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

BIOA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲98 buying vs 81 selling
  • ▼Held by funds -3.6 pts
  • ▲Funds holding +11
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding162151+7.3%
In funds' top 1027−71.4%
Held by funds78.5%82.1%−3.6 pts
New / increased46 / 5228 / 60+11.4%
Reduced / sold out46 / 3540 / 19+37.3%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See BIOA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

BIOA Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$7.8M9 sales · 4 insiders
100% of the selling was under pre-arranged trading plans.
2025-12 sold $918K2026-01 sold $4.9M2026-02 sold $139K2026-03 sold $151K2026-04 sold $157K2026-06 sold $1.6MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 30Shane BartonPrincipal Accounting OfficerSale plan62,566$25.20$1.6M
Apr 1Paul D RubinChief Medical OfficerSale plan8,820$17.81$157K
Mar 2Paul D RubinChief Medical OfficerSale plan7,433$20.30$151K
Feb 2Paul D RubinChief Medical OfficerSale plan7,433$18.75$139K
Jan 13Dov A Goldstein MdCFOSale plan27,000$19.70$532K
Jan 13Kristen FortneyCEOSale plan233,107$18.12$4.2M
Every insider buy and sale for BIOA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See BIOA insider trades →

From SEC Form 4 filings by BIOA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BIOA is in one of them and how their past BIOA trades turned out.

BIOA in the AI portfolios
Loading…

BIOA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered BIOA in an article yet. Here's the latest on the wider market.

BIOA in the news

BIOA Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Jul 13
Who traded BIOA · since 2014
Latest 4 filings
$1K – $15KTraded Jun 9, 2016Filed Jul 13, 2016
$1K – $15KTraded Oct 10, 2014Filed Nov 20, 2014
$1K – $15KTraded Oct 9, 2014Filed Nov 20, 2014
$15K – $50KTraded Jul 24, 2014Filed Aug 17, 2014
PersonTypeAmountTradedFiledDelay
Suzan DelBeneD · WASell$1K – $15KJun 9, 2016Jul 13, 201634 d
Suzan DelBeneD · WABuy$1K – $15KOct 10, 2014Nov 20, 201441 d
Suzan DelBeneD · WABuy$1K – $15KOct 9, 2014Nov 20, 201442 d
Suzan DelBeneD · WABuy$15K – $50KJul 24, 2014Aug 17, 201424 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About BioAge Labs

BioAge Labs is a biopharmaceutical company based in Emeryville, California, that develops drug candidates for chronic cardiometabolic diseases such as heart disease, diabetes and obesity. Its approach uses human datasets from long-term biobanked samples and health records to find biological pathways linked to aging. Its lead candidate, BGE-102, is an oral NLRP3 inhibitor being studied for cardiovascular risk and diabetic macular edema. The company is also developing apelin receptor agonists for obesity and works with Eli Lilly and Novartis on earlier stage programs.

Headquarters
Emeryville, CA